GB0022216D0 - Human FAP-a-specific antibodies for use in cancer therapy - Google Patents
Human FAP-a-specific antibodies for use in cancer therapyInfo
- Publication number
- GB0022216D0 GB0022216D0 GB0022216A GB0022216A GB0022216D0 GB 0022216 D0 GB0022216 D0 GB 0022216D0 GB 0022216 A GB0022216 A GB 0022216A GB 0022216 A GB0022216 A GB 0022216A GB 0022216 D0 GB0022216 D0 GB 0022216D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- specific antibodies
- cancer therapy
- human fap
- fap
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0022216A GB0022216D0 (en) | 2000-09-11 | 2000-09-11 | Human FAP-a-specific antibodies for use in cancer therapy |
AU2001256325A AU2001256325A1 (en) | 2000-03-17 | 2001-03-16 | Human and humanized fap-alpha-specific antibodies |
JP2001567798A JP2003530092A (en) | 2000-03-17 | 2001-03-16 | Human FAP-α-specific antibody |
EP01929604A EP1268550A2 (en) | 2000-03-17 | 2001-03-16 | Human fap-alpha-specific antibodies |
PCT/EP2001/004716 WO2001068708A2 (en) | 2000-03-17 | 2001-03-16 | Human and humanized fap-alpha-specific antibodies |
CA002401252A CA2401252A1 (en) | 2000-03-17 | 2001-03-16 | Human and humanized fap-alpha-specific antibodies |
US09/811,737 US20020099180A1 (en) | 2000-03-17 | 2001-03-19 | Human FAP-alpha-specific antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0022216A GB0022216D0 (en) | 2000-09-11 | 2000-09-11 | Human FAP-a-specific antibodies for use in cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0022216D0 true GB0022216D0 (en) | 2000-10-25 |
Family
ID=9899200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0022216A Ceased GB0022216D0 (en) | 2000-03-17 | 2000-09-11 | Human FAP-a-specific antibodies for use in cancer therapy |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB0022216D0 (en) |
-
2000
- 2000-09-11 GB GB0022216A patent/GB0022216D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2386120B (en) | Differentiated cells suitable for human therapy | |
LT2940044T (en) | Anti-tnf alpha antibodies for use in therapy | |
EP1311262A4 (en) | Cancer treatment by combination therapy | |
EE04528B1 (en) | Aralam laminates for use in therapy for spirofurop ridins | |
GB0016787D0 (en) | Compounds useful in therapy | |
IL157993A0 (en) | Molecular conjugates for use in cancer treatment and methods for the preparation thereof | |
HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
IL156690A0 (en) | Specific human antibodies for selective cancer therapy | |
HUP0300339A3 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
GB0005257D0 (en) | Breast cancer hormonal therapy | |
EP1385879A4 (en) | Reproductive cancer diagnosis and therapy | |
AU2002215111A1 (en) | Ruthenium-aryl-compounds in cancer therapy | |
GB0026015D0 (en) | Cancer treatment | |
GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy | |
GB2374018B (en) | Ultrasound therapy | |
GB9906130D0 (en) | Compounds for use in therapy | |
GB0014046D0 (en) | Compounds useful in therapy | |
SI1157041T1 (en) | Antibodies for cancer therapy and diagnosis | |
SI1251850T1 (en) | Use of a combination preparation in cancer therapy | |
GB0130733D0 (en) | Therapeutic compounds and their use in therapy | |
GB0015676D0 (en) | Aryl compounds their preparation and their use in therapy | |
GB0024673D0 (en) | Therapeutic antibodies | |
GB0030058D0 (en) | Use of compounds in therapy | |
GB0017625D0 (en) | Use of compounds in therapy | |
GB0012945D0 (en) | Use of compounds in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |